Mink Therapeutics Inc (INKT)

$9.41 -0.33 (-3.39%)
Market Cap 44.41M
Revenue (ttm) 0.00
Net Income (ttm) -9.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 28,200
Avg Vol 344,358
Day's Range N/A - N/A
Shares Out 4.69M
Stochastic %K 7%
Beta 0.35
Analysts Strong Sell
Price Target $39.00

Company Profile

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilim...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 994 8250
Address:
149 Fifth Avenue, Suite 500, New York, United States
Spartrap
Spartrap Mar. 20 at 12:18 AM
$INKT ooh my my my look what I found here https://www.abstractsonline.com/pp8/#!/21436/presentation/12166 April the 20th mark the date. Abstract is still embargoed at this time. Could be extremely tasty.
0 · Reply
BenUnknown
BenUnknown Mar. 19 at 4:08 PM
$INKT added a little more here today
1 · Reply
Spartrap
Spartrap Mar. 19 at 2:08 PM
$INKT $9.15 avg YE $54 PT
2 · Reply
Marcoseneg
Marcoseneg Mar. 17 at 7:08 PM
$INKT
0 · Reply
Rounderssss4
Rounderssss4 Mar. 17 at 2:47 PM
$INKT send it
0 · Reply
2_logs_higher
2_logs_higher Mar. 17 at 1:55 PM
$AGEN & $INKT
0 · Reply
haimelm10
haimelm10 Mar. 17 at 6:30 AM
$INKT Do you think IPO is cooming? I want to buy INKT but afraid
2 · Reply
2_logs_higher
2_logs_higher Mar. 16 at 9:26 PM
$AGEN & $INKT 10K: page 62 of 145: MiNK closed an IPO in October 2021. As of December 31, 2025, we owned 2,177,286 shares, representing approximately 46% of MiNK’s common stock.
2 · Reply
Spartrap
Spartrap Mar. 16 at 7:56 PM
$INKT I've been buying like crazy in the low 9s. Spider senses are tingling 🕸️
1 · Reply
Rounderssss4
Rounderssss4 Mar. 16 at 7:14 PM
$INKT where and when is the bounce here seems over sold?
0 · Reply
Latest News on INKT
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

Mar 17, 2026, 7:30 AM EDT - 4 days ago

MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?

Mar 11, 2026, 9:24 AM EDT - 10 days ago

Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?

MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally

Mar 10, 2026, 9:47 AM EDT - 11 days ago

MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally

MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers

Mar 10, 2026, 5:30 AM EDT - 11 days ago

MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia

Feb 3, 2026, 9:30 PM EST - 6 weeks ago

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia

MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease

Jan 8, 2026, 12:00 PM EST - 2 months ago

MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

Nov 20, 2025, 11:42 AM EST - 4 months ago

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

Nov 7, 2025, 9:00 AM EST - 4 months ago

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

Sep 29, 2025, 7:30 AM EDT - 6 months ago

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

Sep 25, 2025, 7:30 AM EDT - 6 months ago

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

Sep 18, 2025, 7:30 AM EDT - 6 months ago

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

Aug 14, 2025, 7:30 AM EDT - 7 months ago

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

Jul 31, 2025, 8:30 AM EDT - 8 months ago

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

Jul 15, 2025, 8:21 AM EDT - 8 months ago

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?

Jul 11, 2025, 12:33 PM EDT - 9 months ago

Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Jun 10, 2025, 1:33 PM EDT - 10 months ago

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

Jun 2, 2025, 9:29 AM EDT - 10 months ago

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

May 15, 2025, 7:30 AM EDT - 11 months ago

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

Mar 18, 2025, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Mar 4, 2025, 7:30 AM EST - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

Feb 24, 2025, 8:30 AM EST - 1 year ago

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 1 year ago

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

Jan 23, 2025, 2:13 PM EST - 1 year ago

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

Dec 18, 2024, 9:45 AM EST - 1 year ago

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

Nov 11, 2024, 7:30 AM EST - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

Nov 7, 2024, 10:00 AM EST - 1 year ago

MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

Oct 31, 2024, 9:15 AM EDT - 1 year ago

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

Oct 8, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

Oct 4, 2024, 9:10 AM EDT - 1 year ago

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Sep 3, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

MiNK Reports Second Quarter 2024 Results and Business Update

Aug 13, 2024, 7:00 AM EDT - 1 year ago

MiNK Reports Second Quarter 2024 Results and Business Update

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

Aug 1, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

Jul 31, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

May 22, 2024, 7:30 AM EDT - 1 year ago

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

MiNK Reports First Quarter 2024 Results

May 14, 2024, 7:30 AM EDT - 2 years ago

MiNK Reports First Quarter 2024 Results

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

May 13, 2024, 7:30 AM EDT - 2 years ago

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

Apr 30, 2024, 7:30 AM EDT - 2 years ago

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

Apr 8, 2024, 12:00 PM EDT - 2 years ago

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

MiNK Reports Fourth Quarter and Year-End 2023 Results

Mar 21, 2024, 7:00 AM EDT - 2 years ago

MiNK Reports Fourth Quarter and Year-End 2023 Results

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Mar 7, 2024, 7:30 AM EST - 2 years ago

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

Mar 6, 2024, 8:30 AM EST - 2 years ago

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

Jan 30, 2024, 8:00 AM EST - 2 years ago

MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

Dec 20, 2023, 7:30 AM EST - 2 years ago

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

MiNK Therapeutics Reports Third Quarter 2023 Results

Nov 9, 2023, 7:00 AM EST - 2 years ago

MiNK Therapeutics Reports Third Quarter 2023 Results

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Nov 3, 2023, 12:00 PM EDT - 2 years ago

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

Oct 30, 2023, 8:00 AM EDT - 2 years ago

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Sep 27, 2023, 9:05 AM EDT - 2 years ago

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

MiNK Therapeutics to Participate in September Investor Conferences

Aug 24, 2023, 8:30 AM EDT - 2 years ago

MiNK Therapeutics to Participate in September Investor Conferences

MiNK Therapeutics Reports Second Quarter 2023 Results

Aug 10, 2023, 7:30 AM EDT - 2 years ago

MiNK Therapeutics Reports Second Quarter 2023 Results

MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update

Jul 28, 2023, 8:30 AM EDT - 2 years ago

MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update

Spartrap
Spartrap Mar. 20 at 12:18 AM
$INKT ooh my my my look what I found here https://www.abstractsonline.com/pp8/#!/21436/presentation/12166 April the 20th mark the date. Abstract is still embargoed at this time. Could be extremely tasty.
0 · Reply
BenUnknown
BenUnknown Mar. 19 at 4:08 PM
$INKT added a little more here today
1 · Reply
Spartrap
Spartrap Mar. 19 at 2:08 PM
$INKT $9.15 avg YE $54 PT
2 · Reply
Marcoseneg
Marcoseneg Mar. 17 at 7:08 PM
$INKT
0 · Reply
Rounderssss4
Rounderssss4 Mar. 17 at 2:47 PM
$INKT send it
0 · Reply
2_logs_higher
2_logs_higher Mar. 17 at 1:55 PM
$AGEN & $INKT
0 · Reply
haimelm10
haimelm10 Mar. 17 at 6:30 AM
$INKT Do you think IPO is cooming? I want to buy INKT but afraid
2 · Reply
2_logs_higher
2_logs_higher Mar. 16 at 9:26 PM
$AGEN & $INKT 10K: page 62 of 145: MiNK closed an IPO in October 2021. As of December 31, 2025, we owned 2,177,286 shares, representing approximately 46% of MiNK’s common stock.
2 · Reply
Spartrap
Spartrap Mar. 16 at 7:56 PM
$INKT I've been buying like crazy in the low 9s. Spider senses are tingling 🕸️
1 · Reply
Rounderssss4
Rounderssss4 Mar. 16 at 7:14 PM
$INKT where and when is the bounce here seems over sold?
0 · Reply
Spartrap
Spartrap Mar. 16 at 1:47 PM
$INKT so many breadcrumbs. Something meaningful is gonna happen here very soon
0 · Reply
2_logs_higher
2_logs_higher Mar. 14 at 7:15 PM
$AGEN & $INKT: China competition, With FDA go ahead, a China biotech notches a first in cell therapy testing Z says Agen is in the diamond lane whereas China is crash-investigation tow truck area. https://www.biopharmadive.com/news/unixell-fda-china-biotech-epilepsy-cell-therapy-human-testing/814662/
0 · Reply
Spartrap
Spartrap Mar. 14 at 1:48 PM
$INKT Historically the company has always published a PR during the first week of March announcing the Q4 ER two weeks later. So they are ~9 days late. Don't ask me what it means, it's an observation. Also Tuesday AH, the titles of AACR abstracts will be published. We could see a PR if they have something up
1 · Reply
Turnpiker
Turnpiker Mar. 13 at 5:47 PM
$INKT $IBRX I don’t usually crosspost but we have a partner in INKT. They were present at Saudi-US forum. I think they’re playing a part in Leonardo. Don’t sleep on them. IBRX Leonardo/Ai PR due soon may reveal partnership. Or, the Saudi-US investment PR I’m expecting may outline their involvement. I started a position at INKT
3 · Reply
Joby099
Joby099 Mar. 13 at 3:23 PM
$ATPC $INKT $VTAK $AIB $MRNO
0 · Reply
Peak5306
Peak5306 Mar. 13 at 10:46 AM
$INKT WTF happened 😳
1 · Reply
Joby099
Joby099 Mar. 13 at 8:39 AM
$ATPC $INKT $VTAK $AIB $MRNO
0 · Reply
Harunkaraca
Harunkaraca Mar. 13 at 12:29 AM
$INKT wooow what a Shit show
0 · Reply
Joby099
Joby099 Mar. 12 at 8:12 PM
$ATPC $INKT $VTAK $AIB $MRNO
0 · Reply
Biotechguy21
Biotechguy21 Mar. 12 at 2:55 PM
$AGEN it’s almost pos time for one of the worst stocks out there. Just like $INKT 🤡🤡💩💩😂😂
0 · Reply
pAmdd
pAmdd Mar. 12 at 12:43 PM
$INKT 8 is a target here
0 · Reply
Joby099
Joby099 Mar. 12 at 8:12 AM
$ATPC $INKT $VTAK $AIB $MRNO
0 · Reply